SCHEMBL3392274

SCHEMBL3392274

Cc1ccc(Nc2ncc(NC(=O)c3c(F)cccc3F)s2)cc1

nearest known ligand 0.51

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 5/20 0.51
KMT2A Q03164 5/20 0.51
RAB9A P51151 5/20 0.51
SMN1; SMN2 Q16637 3/20 0.51
MAPT P10636 1/20 0.47
RXFP1 Q9HBX9 1/20 0.47
GAA P10253 1/20 0.46
LMNA P02545 1/20 0.46
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
STIM1 Q13586 1/20 0.44
ORAI1 Q96D31 1/20 0.44
JAK2 O60674 1/20 0.43
JAK1 P23458 1/20 0.43
TYK2 P29597 1/20 0.43
HTT P42858 1/20 0.43
NOD2 Q9HC29 1/20 0.43
KDR P35968 1/20 0.43
NPC1 O15118 4/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3394645 0.87 RAB9A (0.54) MEN1KMT2ARAB9ASMN1; SMN2MAPT
SCHEMBL3397250 0.79 RAB9A (0.61) MEN1KMT2ARAB9ASMN1; SMN2MAPT
SCHEMBL3394845 0.78 MEN1 (0.57) MEN1KMT2ARAB9ASMN1; SMN2MAPT
SCHEMBL3391621 0.78 MAPK14 (0.55) MEN1KMT2ARAB9ASMN1; SMN2GAA
SCHEMBL3398555 0.77 RAB9A (0.55) MEN1KMT2ARAB9ASMN1; SMN2MAPT
SCHEMBL3398516 0.77 RAB9A (0.58) MEN1KMT2ARAB9ASMN1; SMN2RXFP1
SCHEMBL2367620 0.76 MAPT (0.81) MEN1KMT2AMAPTLMNA
SCHEMBL3392231 0.74 MEN1 (0.55) MEN1KMT2ARAB9ASMN1; SMN2MAPT
SCHEMBL3390828 0.74 MEN1 (0.56) MEN1KMT2ARAB9ASMN1; SMN2MAPT
SCHEMBL3392255 0.73 SMN1; SMN2 (0.53) MEN1KMT2ARAB9ASMN1; SMN2MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100216795-A1 TNIK INHIBITOR AND THE USE YAMADA TESSHI 2010-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100216795-A1 TNIK INHIBITOR AND THE USE TNIK, TNNI3K, TNK1 MEN1 3798/4885KMT2A 831/4885RAB9A 1982/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.